Hansoh Pharmaceutical Marks Eighth Consecutive Year in Top 3 of China's Best Industrial Enterprises in Pharmaceutical R&D Pipeline

From September 6 to 9, the 41st National Pharmaceutical Industry Information Annual Meeting was held in Chengdu, where the much-anticipated MIIT China Pharmaceutical Industry Top 100 list and a series of sub-lists were released. Hansoh Pharma's key subsidiary, Hosa Pharmaceutical, was listed among the "Top 100 Enterprises in China's Pharmaceutical Industry," and ranked among the top three on the "Best Industrial Enterprises in China's Pharmaceutical R&D Product Line" list for eight consecutive years thanks to its leading innovation capabilities and comprehensive competitiveness.

"Best Industrial Enterprise in China's Pharmaceutical R&D Pipeline" is one of the most authoritative and representative industry selection events in China. The list is strictly selected by a professional judging panel based on objective data and research analysis. In the current environment of deepening reform in the pharmaceutical industry both in China and abroad, the listed companies have fully demonstrated excellent innovative development resilience.

In the first half of 2024, Hansoh Pharma's R&D investment reached approximately 1.196 billion yuan, increasing by about 28.7% year-on-year, hitting a new high. Currently, the company has established four R&D centers in Maryland, USA, and in Shanghai, Changzhou, and Lianyungang in China, with over 1,700 professional R&D staff. To further build a frontier scientific innovation hub and technological highland, in March 2024, the global R&D headquarters of Hansoh Pharma commenced construction in Shanghai, with a total project area exceeding 90,000 square meters.

Driven by the dual engines of independent research and development and external cooperation, Hansoh Pharma always adheres to the unmet clinical needs as the guidance. Relying on internationally cutting-edge technology platforms such as ADC, monoclonal antibodies, bispecific antibodies, siRNA, and fusion proteins, the company continues to deepen its advantageous sector in anti-tumor therapies. It is also accelerating the layout in disease areas such as anti-infection, central nervous system, metabolism, and autoimmune diseases. Currently, it has more than 30 innovative drugs undergoing over 50 clinical trials.

"Innovation + Internationalization" has become the new driving force for Hansoh Pharma's sustainable growth. While deeply focusing on independent research and development, the company has introduced a total of 11 cooperative projects and successfully granted the overseas rights of two self-developed ADC products to leading global pharmaceutical enterprises, aiming to accelerate the transformation of R&D achievements to benefit patients in China and worldwide.